ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, BCR-ABL1 expression induces SET-mediated inactivation of PP2A, whose lost activity in CML can be reestablished by PP2A activating drugs FTY720 (14–17).